Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schweizer

Showing results (221-230 of 267) with videos related to

Pageof 27
Sort By:
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
Pageof 27

Showing results (221-230 of 267) with videos related to

Sort By:
Pageof 27
Radiology|March 31, 2026
PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Alireza Ghodsi, Lukas Owens, Ridvan Arda Demirci, et al.
American Journal of Nuclear Medicine and Molecular Imaging|January 22, 2026
Results from a prospective registry of <sup>18</sup>F-Fluciclovine PET/CT use in prostate cancer management: a cautionary lesson for implementation of PSMA PETSteven Blinka, Risa L Wong, Sarah K Holt, et al.
Bladder Cancer (Amsterdam, Netherlands)|June 10, 2021
Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomesLeonidas N Diamantopoulos, Ali Raza Khaki, Petros Grivas, et al.
Prostate Cancer and Prostatic Diseases|December 23, 2022
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancerMichael T Schweizer, Roman Gulati, Todd Yezefski, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
JCI Insight|May 31, 2019
Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsyBrian R Winters, Navonil De Sarkar, Sonali Arora, et al.
The Prostate|September 13, 2021
Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutationsAlexandra O Sokolova, Catherine H Marshall, Rebeca Lozano, et al.
JCO Precision Oncology|May 25, 2019
Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsMichael T Schweizer, Emmanuel S Antonarakis, Tarek A Bismar, et al.
European Urology Oncology|February 7, 2025
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after <sup>177</sup>Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair GenesRuben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, et al.
The Prostate|March 23, 2021
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancerLaura S Graham, Lawrence D True, Roman Gulati, et al.
Pageof 27